Treatment regimens using anti-nkg2a antibodies
US-2024368281-A1 · Nov 7, 2024 · US
This page is not indexed by search engines while we improve data quality.
Andre Pascale patents
Andre Pascale is listed as an inventor on 25 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Andre Pascale |
| Total patents | 25 |
| First publication | Oct 8, 2015 |
| Latest publication | Nov 7, 2024 |
Notable patents
Publications ranked by popularity score, then publication date.
Treatment regimens using anti-NKG2A antibodies
US-12037392-B2 · Jul 16, 2024 · US
Neutralization of inhibitory pathways in lymphocytes
US-2023303691-A1 · Sep 28, 2023 · US
Neutralization of inhibitory pathways in lymphocytes
US-2023235060-A1 · Jul 27, 2023 · US
Neutralization of inhibitory pathways in lymphocytes
US-11572410-B2 · Feb 7, 2023 · US
Treatment of cancers using anti-NKG2A agents
US-11225519-B2 · Jan 18, 2022 · US
Treatment regimens using anti-nkg2a antibodies
US-2021238285-A1 · Aug 5, 2021 · US
Neutralization of inhibitory pathways in lymphocytes
US-2021122821-A1 · Apr 29, 2021 · US
Neutralization of inhibitory pathways in lymphocytes
US-10870700-B2 · Dec 22, 2020 · US
Neutralization of inhibitory pathways in lymphocytes
US-2020332008-A1 · Oct 22, 2020 · US
Recent patents
Latest publications not already listed above.
Treatment regimens using anti-nkg2a antibodies
US-2020299383-A1 · Sep 24, 2020 · US
Neutralization of inhibitory pathways in lymphocytes
US-10711063-B2 · Jul 14, 2020 · US
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
US-10688180-B2 · Jun 23, 2020 · US
Treatment regimens using anti-NKG2A antibodies
US-10676523-B2 · Jun 9, 2020 · US
Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
US-10494433-B2 · Dec 3, 2019 · US
Treatment of cancers using anti-nkg2a agents
US-2019322744-A1 · Oct 24, 2019 · US
Treatment of cancers using anti-NKG2A agents
US-10329348-B2 · Jun 25, 2019 · US
Neutralization of inhibitory pathways in lymphocytes
US-2019031755-A1 · Jan 31, 2019 · US
Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
US-2018117147-A1 · May 3, 2018 · US
Treatment of cancers using anti-nkg2a agents
US-2017313773-A1 · Nov 2, 2017 · US
Treatment regimens using anti-nkg2a antibodies
US-2017298131-A1 · Oct 19, 2017 · US
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
US-9789182-B2 · Oct 17, 2017 · US
Neutralization of inhibitory pathways in lymphocytes
US-2017291947-A1 · Oct 12, 2017 · US
Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
US-2016257750-A1 · Sep 8, 2016 · US
Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
US-2015283234-A1 · Oct 8, 2015 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Innate Pharma | 25 |
| Bristol Myers Squibb Co | 6 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| C07K16/2803 | 25 |
| A61P35/00 | 25 |
| C07K2317/76 | 21 |
| C07K2317/24 | 21 |
| A61K2039/545 | 21 |